Literature DB >> 21680036

Increased organ sparing using shape-based treatment plan optimization for intensity modulated radiation therapy of pancreatic adenocarcinoma.

Steven F Petit1, Binbin Wu, Michael Kazhdan, André Dekker, Patricio Simari, Rachit Kumar, Russel Taylor, Joseph M Herman, Todd McNutt.   

Abstract

PURPOSE: To develop a model to assess the quality of an IMRT treatment plan using data of prior patients with pancreatic adenocarcinoma.
METHODS: The dose to an organ at risk (OAR) depends in large part on its orientation and distance to the planning target volume (PTV). A database of 33 previously treated patients with pancreatic cancer was queried to find patients with less favorable PTV-OAR configuration than a new case. The minimal achieved dose among the selected patients should also be achievable for the OAR of the new case. This way the achievable doses to the OARs of 25 randomly selected pancreas cancer patients were predicted. The patients were replanned to verify if the predicted dose could be achieved. The new plans were compared to their original clinical plans.
RESULTS: The predicted doses were achieved within 1 and 2 Gy for more than 82% and 94% of the patients, respectively, and were a good approximation of the minimal achievable doses. The improvement after replanning was 1.4 Gy (range 0-4.6 Gy) and 1.7 Gy (range 0-6.3 Gy) for the mean dose to the liver and the kidneys, respectively, without compromising target coverage or increasing radiation dose to the bowel, cord or stomach.
CONCLUSIONS: The model could accurately predict the achievable doses, leading to a considerable decrease in dose to the OARs and an increase in treatment planning efficiency.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21680036      PMCID: PMC3578316          DOI: 10.1016/j.radonc.2011.05.025

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  16 in total

1.  Lexicographic ordering: intuitive multicriteria optimization for IMRT.

Authors:  Kyung-Wook Jee; Daniel L McShan; Benedick A Fraass
Journal:  Phys Med Biol       Date:  2007-03-07       Impact factor: 3.609

Review 2.  Chemoradiotherapy for unresectable pancreatic cancer.

Authors:  Edgar Ben-Josef; Theodore S Lawrence
Journal:  Int J Clin Oncol       Date:  2008-05-08       Impact factor: 3.402

3.  Geometric factors influencing dosimetric sparing of the parotid glands using IMRT.

Authors:  Margie A Hunt; Andrew Jackson; Ashwatha Narayana; Nancy Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-09-01       Impact factor: 7.038

4.  Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer.

Authors:  M J Zelefsky; Z Fuks; L Happersett; H J Lee; C C Ling; C M Burman; M Hunt; T Wolfe; E S Venkatraman; A Jackson; M Skwarchuk; S A Leibel
Journal:  Radiother Oncol       Date:  2000-06       Impact factor: 6.280

5.  Dose-volume objectives in multi-criteria optimization.

Authors:  Tarek Halabi; David Craft; Thomas Bortfeld
Journal:  Phys Med Biol       Date:  2006-07-20       Impact factor: 3.609

6.  Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.

Authors:  Edgar Ben-Josef; Anthony F Shields; Ulka Vaishampayan; Vainutis Vaitkevicius; Basil F El-Rayes; Patrick McDermott; Jay Burmeister; Todd Bossenberger; Philip A Philip
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-06-01       Impact factor: 7.038

7.  Intra-operative radiotherapy (IORT) in pancreatic cancer: joint analysis of the ISIORT-Europe experience.

Authors:  Vincenzo Valentini; Felipe Calvo; Michele Reni; Robert Krempien; Felix Sedlmayer; Markus W Buchler; Valerio Di Carlo; Giovanni B Doglietto; Gerd Fastner; José L Garcia-Sabrido; GianCarlo Mattiucci; Alessio G Morganti; Paolo Passoni; Falk Roeder; Giuseppe R D'Agostino
Journal:  Radiother Oncol       Date:  2008-08-30       Impact factor: 6.280

8.  A new concept for interactive radiotherapy planning with multicriteria optimization: first clinical evaluation.

Authors:  Christian Thieke; Karl-Heinz Küfer; Michael Monz; Alexander Scherrer; Fernando Alonso; Uwe Oelfke; Peter E Huber; Jürgen Debus; Thomas Bortfeld
Journal:  Radiother Oncol       Date:  2007-09-24       Impact factor: 6.280

Review 9.  Intraoperative radiotherapy in pancreatic cancer: a systematic review.

Authors:  Alberto Ruano-Ravina; Raquel Almazán Ortega; Ferrran Guedea
Journal:  Radiother Oncol       Date:  2008-01-15       Impact factor: 6.280

Review 10.  Radiation response of the central nervous system.

Authors:  T E Schultheiss; L E Kun; K K Ang; L C Stephens
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-03-30       Impact factor: 7.038

View more
  25 in total

1.  Evaluating inter-campus plan consistency using a knowledge based planning model.

Authors:  Sean L Berry; Rongtao Ma; Amanda Boczkowski; Andrew Jackson; Pengpeng Zhang; Margie Hunt
Journal:  Radiother Oncol       Date:  2016-07-06       Impact factor: 6.280

2.  Quantifying Unnecessary Normal Tissue Complication Risks due to Suboptimal Planning: A Secondary Study of RTOG 0126.

Authors:  Kevin L Moore; Rachel Schmidt; Vitali Moiseenko; Lindsey A Olsen; Jun Tan; Ying Xiao; James Galvin; Stephanie Pugh; Michael J Seider; Adam P Dicker; Walter Bosch; Jeff Michalski; Sasa Mutic
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-03       Impact factor: 7.038

3.  Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer.

Authors:  Jordan Kharofa; Susan Tsai; Tracy Kelly; Clint Wood; Ben George; Paul Ritch; Lauren Wiebe; Kathleen Christians; Douglas B Evans; Beth Erickson
Journal:  Radiother Oncol       Date:  2014-10-15       Impact factor: 6.280

4.  Accurate prediction of nodal status in preoperative patients with pancreatic ductal adenocarcinoma using next-gen nanoparticle.

Authors:  Shaunagh McDermott; Sarah P Thayer; Carlos Fernandez-Del Castillo; Mari Mino-Kenudson; Ralph Weissleder; Mukesh G Harisinghani
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

5.  Use of a constrained hierarchical optimization dataset enhances knowledge-based planning as a quality assurance tool for prostate bed irradiation.

Authors:  Yen Hwa Lin; Linda X Hong; Margie A Hunt; Sean L Berry
Journal:  Med Phys       Date:  2018-09-21       Impact factor: 4.071

6.  Comparative Study of Auto Plan and Manual Plan for Nasopharyngeal Carcinoma Intensity-Modulated Radiation Therapy.

Authors:  Xin Xin; Chuandong Cheng; Churong Li; Jie Li; Pei Wang; Gang Yin; Jinyi Lang
Journal:  Cancer Manag Res       Date:  2020-12-02       Impact factor: 3.989

7.  Clinical target volume delineation including elective nodal irradiation in preoperative and definitive radiotherapy of pancreatic cancer.

Authors:  Luciana Caravatta; Giuseppina Sallustio; Fabio Pacelli; Gilbert D A Padula; Francesco Deodato; Gabriella Macchia; Mariangela Massaccesi; Vincenzo Picardi; Savino Cilla; Alfonso Marinelli; Numa Cellini; Vincenzo Valentini; Alessio G Morganti
Journal:  Radiat Oncol       Date:  2012-06-12       Impact factor: 3.481

8.  Automated inverse optimization facilitates lower doses to normal tissue in pancreatic stereotactic body radiotherapy.

Authors:  Ivaylo B Mihaylov; Eric A Mellon; Raphael Yechieli; Lorraine Portelance
Journal:  PLoS One       Date:  2018-01-19       Impact factor: 3.240

9.  Knowledge-based radiation therapy (KBRT) treatment planning versus planning by experts: validation of a KBRT algorithm for prostate cancer treatment planning.

Authors:  Obioma Nwankwo; Hana Mekdash; Dwi Seno Kuncoro Sihono; Frederik Wenz; Gerhard Glatting
Journal:  Radiat Oncol       Date:  2015-05-10       Impact factor: 3.481

10.  An Automated Treatment Plan Quality Control Tool for Intensity-Modulated Radiation Therapy Using a Voxel-Weighting Factor-Based Re-Optimization Algorithm.

Authors:  Ting Song; Nan Li; Masoud Zarepisheh; Yongbao Li; Quentin Gautier; Linghong Zhou; Loren Mell; Steve Jiang; Laura Cerviño
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.